CN Patent

CN1726016A — 阿尔茨海默氏病的预防和治疗

Assigned to Aventis Pharma SA · Expires 2006-01-25 · 20y expired

What this patent protects

本发明涉及胆汁酸肠再摄取抑制剂在预防和治疗阿尔茨海默氏病中的用途，所述抑制剂可以与HMG－CoA还原酶抑制剂、胆固醇摄取抑制剂、胆固醇合成抑制剂或APP促分泌酶抑制剂联合给药。

USPTO Abstract

本发明涉及胆汁酸肠再摄取抑制剂在预防和治疗阿尔茨海默氏病中的用途，所述抑制剂可以与HMG－CoA还原酶抑制剂、胆固醇摄取抑制剂、胆固醇合成抑制剂或APP促分泌酶抑制剂联合给药。

Drugs covered by this patent

Patent Metadata

Patent number
CN1726016A
Jurisdiction
CN
Classification
—
Expires
2006-01-25
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.